What happened
BillionToOne, Inc. (NASDAQ: BLLN) said Chairman and CEO Oguzhan Atay sold 19,334 shares on 2026-10-12 at $91.57 to $97.61 each. The sale brought in about $1.82 million. The filing also says Atay exercised 16,667 stock options the same day. The options were fully vested and exercisable, and the form lists a $2.8 exercise price. The trades were made under a Rule 10b5-1 plan adopted on June 5, 2026.
The reported sale prices were weighted averages across multiple trades. After the sale, Atay held 151,835 shares. The filing also shows 476,962 derivative securities beneficially owned. The form identifies Atay as a director as well as Chairman and CEO.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| shares sold | 19,334 shares | SEC Form 4 | |
| sale proceeds | $1.82 million | SEC Form 4 | |
| shares held after the sale | 151,835 shares | SEC Form 4 | |
| option shares exercised | 16,667 shares | SEC Form 4 | |
| share of pre-trade holding sold | 11.3% | Calculated from SEC Form 4 |
Why it matters
OptimistFi's case is that BillionToOne works if its prenatal and oncology molecular tests stay differentiated enough to keep winning orders and reimbursement while lab scale turns that volume into cash generation. This filing is mixed for that view. Atay sold shares under a preplanned Rule 10b5-1 arrangement, but he still held 151,835 shares and 476,962 derivative securities after the sale. Atay's 19,334 shares were about 11.3% of the holding before the trade, according to OptimistFi's calculation.
The same-day option exercise is a reason to be careful. It can fit routine liquidity management, so the trade may reflect a preset plan rather than a change in conviction. Even so, Atay still held 151,835 shares after the sale, which keeps insider exposure in place. That gives investors a new ownership baseline for the chief executive.
Browse: stock research on every company OptimistFi covers
What's next
BillionToOne's next quarterly report is the next scheduled check on whether the company keeps winning orders and reimbursement. Results that show continued growth and cash generation would strengthen OptimistFi's case. Weaker numbers would weaken it. The report will give investors the next operating read after this planned insider sale. If it shows better volume and reimbursement, the case strengthens. If it weakens, the sale matters more.
More from OptimistFi
- BLLN stock: the BillionToOne thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Filed October 14, 2026
- Calculated from SEC Form 4 — 19,334 shares sold was about 11.3% of the holding before the trade
Read the full OptimistFi thesis on BillionToOne, Inc.: https://optimistfi.com/stocks/BLLN
See what would break the BillionToOne, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full BillionToOne, Inc. investment case, its status and the next test to watch live on the BillionToOne, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
